eXoZymes, Inc. (EXOZ) - Net Assets
Based on the latest financial reports, eXoZymes, Inc. (EXOZ) has net assets worth $1.53 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($4.02 Million) and total liabilities ($2.49 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check eXoZymes, Inc. tangible equity quality to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.53 Million |
| % of Total Assets | 38.02% |
| Annual Growth Rate | 29.79% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 58.46 |
eXoZymes, Inc. - Net Assets Trend (2021–2025)
This chart illustrates how eXoZymes, Inc.'s net assets have evolved over time, based on quarterly financial data. See EXOZ cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for eXoZymes, Inc. (2021–2025)
The table below shows the annual net assets of eXoZymes, Inc. from 2021 to 2025. For live valuation and market cap data, see EXOZ market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $3.40 Million | -67.40% |
| 2024-12-31 | $10.42 Million | +2811.49% |
| 2023-12-31 | $-384.32K | -128.00% |
| 2022-12-31 | $1.37 Million | +14.66% |
| 2021-12-31 | $1.20 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to eXoZymes, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1845458600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $8.00 | 0.00% |
| Other Components | $24.50 Million | 721.23% |
| Total Equity | $3.40 Million | 100.00% |
eXoZymes, Inc. Competitors by Market Cap
The table below lists competitors of eXoZymes, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
RMS Mezzanine A.S.
PR:PVT
|
$66.41 Million |
|
5E Advanced Materials Inc
NASDAQ:FEAM
|
$66.42 Million |
|
Skarbiec Holding S.A.
WAR:SKH
|
$66.42 Million |
|
Interlink Electronics Inc
NASDAQ:LINK
|
$66.44 Million |
|
Territorial Bancorp Inc
NASDAQ:TBNK
|
$66.37 Million |
|
NSTS Bancorp Inc
NASDAQ:NSTS
|
$66.36 Million |
|
Crown Confectionery Co Ltd
KO:264900
|
$66.29 Million |
|
Tainet Communication System
TWO:4905
|
$66.28 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in eXoZymes, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 10,420,775 to 3,397,249, a change of -7,023,526 (-67.4%).
- Net loss of 9,158,734 reduced equity.
- Other factors increased equity by 2,135,208.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-9.16 Million | -269.59% |
| Other Changes | $2.14 Million | +62.85% |
| Total Change | $- | -67.40% |
Book Value vs Market Value Analysis
This analysis compares eXoZymes, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 19.32x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 53.16x to 19.32x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | $0.15 | $7.83 | x |
| 2022-12-31 | $0.17 | $7.83 | x |
| 2023-12-31 | $-0.05 | $7.83 | x |
| 2024-12-31 | $1.28 | $7.83 | x |
| 2025-12-31 | $0.41 | $7.83 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently eXoZymes, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -269.59%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.76x
- Recent ROE (-269.59%) is below the historical average (-105.71%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -101.00% | 0.00% | 0.00x | 1.96x | $-1.33 Million |
| 2022 | -101.72% | 0.00% | 0.00x | 1.96x | $-1.53 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.00 Million |
| 2024 | -56.25% | 0.00% | 0.00x | 1.25x | $-6.90 Million |
| 2025 | -269.59% | 0.00% | 0.00x | 1.76x | $-9.50 Million |
Industry Comparison
This section compares eXoZymes, Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $287,280,896
- Average return on equity (ROE) among peers: -134.04%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| eXoZymes, Inc. (EXOZ) | $1.53 Million | -101.00% | 1.63x | $66.39 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $85.57 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $4.82 Million | -556.02% | 2.44x | $328.21 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $181.82 Million | -56.28% | 0.31x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $200.23 Million | -28.52% | 0.14x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $723.96K | -677.23% | 9.41x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.66 Million | -45.66% | 0.56x | $7.90 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $1.23 Billion | 31.86% | 0.27x | $3.66 Billion |
About eXoZymes, Inc.
eXoZymes, Inc. operates as a development stage biotechnology company. It focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Technologies, Inc. and changed its name to eXoZymes, Inc. in February 2025. eXoZymes, Inc. was incorporated in 2014 and is headquartered in Monrovia, California.